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Renal cell carcinoma (RCC) is characterized by a profound disruption of proapoptotic signaling networks leading to
chemo- and radioresistance. A key mediator of DNA damage-induced apoptosis is the BH3-only protein PUMA.
Given its central role in proapoptotic signaling, we analyzed a series of more than 600 precision-annotated primary
RCC specimens for PUMA protein expression. We found a reduced expression of PUMA in 22.6% of RCCs
analyzed. Unexpectedly, however, PUMA deficiency was not associated with more aggressive tumor
characteristic as expected. Instead, a reduced PUMA expression was associated with a lower TNM stage, lower
histopathologic grade, and more favorable cancer-specific patient survival. A direct correlation in a separate patient
cohort revealed a profound disconnection between PUMA expression and apoptosis as exemplified by the fact
that the tumor with the highest level of apoptotic cells was PUMA deficient. In a series of in vitro studies, we
corroborated these results and discovered the highest propensity to undergo apoptosis in an RCC cell line with
virtually undetectable PUMA expression. At the same time, PUMA expression was not necessarily associated with
stronger apoptosis induction, which underscores the striking functional heterogeneity of PUMA expression and
apoptosis in RCC. Collectively, our findings suggest that PUMA-independent mechanisms of cell death exist and
may play an important role in suppressing malignant progression. They underscore the functional heterogeneity ofReceived 7 September 2015; Accepted 10 November 2015
© 2015 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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understanding of alternative proapoptotic pathways, however, may help to design novel therapeutic strategies
for patients with advanced RCC.
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Renal cell carcinoma (RCC) is characterized by a high degree of
chemo- and radioresistance. The underlying molecular mechanisms
are incompletely understood but very likely entail a profound
disruption of proapoptotic signaling networks.
Chemo- or radiotherapy is believed to function mainly through the
induction of DNA damage. In particular DNA double strand breaks
are highly toxic and trigger an acute cellular response. After induction
of a DNA double strand break, a cascade of events is initiated to halt
cell cycle progression and activate DNA repair mechanisms. If the
damage is too severe to be repaired, cells either enter premature
senescence or undergo apoptosis [1]. Activation of p53 has long been
shown to be a key event in such cell fate decisions, and a number of
critical downstream mechanisms involved in different branches of the
p53-mediated response to DNA damage have been identified.
Specifically, the induction of p53-dependent apoptosis involves the
transcriptional upregulation of PUMA, NOXA, and BAX, which
participate in the mitochondrial pathway of cell death [2].
The BH3-only protein PUMA has been identified as a key
regulator of p53-dependent as well as p53-independent proapoptotic
signaling following genotoxic insults [3–5]. PUMA binds and inhibits
antiapoptotic BCL-2 proteins, thereby relieving the inhibition of the
proapoptotic proteins BAK/BAX to trigger mitochondrial outer
membrane permeabilization and activation of caspases [6]. Members
of the BCL-2 network are frequently disrupted in primary RCCs, and
furthermore, functional studies have shown that the profound DNA
damage resistance of this tumor type involves defects in p53-mediated
proapoptotic signaling [7–10]. We have recently shown that RCC
cells are characterized by a disconnection between p53 activation and
PUMA upregulation that can be reversed by HDAC inhibition [11].
In the present study, we made the surprising discovery that PUMA
deficiency correlates with more favorable clinicopathological charac-
teristics and patient survival in a series of more than 600 RCCs and
not with more aggressive tumor growth as one would predict from the
loss of a proapoptotic protein. To reconcile these findings, we provide
evidence for PUMA-independent apoptosis in vivo as well as in vitro.
The striking functional heterogeneity of PUMA expression and
apoptosis discourages the use of PUMA as predictive biomarker in
RCC but encourages the interrogation of PUMA-independent cell
death mechanisms for the development of innovative strategies to
resensitize RCCs to DNA radio- or chemotherapy.Material and Methods
Cell Culture and Treatment
RCC cell lines A-498, 786-0, Caki-1, Caki-2, RCC-KP, ACHN,
and human embryonic kidney (HEK) 293 cells were all obtained
commercially and maintained as recommended by the distributor
(CLS). The media were supplemented with 10% fetal bovine serum,50 U/ml of penicillin, and 50 μg/ml of streptomycin (Life
Technologies). Cells were treated with staurosporine (Sigma) or
daunorubicin (Toronto Research Chemicals) at the concentrations
indicated for 24 hours. DMSO was used as solvent control.
Immunoblotting
Immunoblot analysis was performed as previously described [11].
Antibodies used for immunoblotting were directed against PUMA
(Cell Signaling), p53 (DO-1; Santa Cruz), phospho-p53 Ser15 (Cell
Signaling), and GAPDH (FL-335; Santa Cruz).
Caspase 3/7 Assay
A luminometric assay (Caspase-Glo 3/7; Promega) was used to
measure apoptotic cell death according to manufacturer's instructions.
Immunohistochemistry
Tissue microarrays (TMAs) were obtained through the biobank of
the National Center for Tumor Diseases Heidelberg. The tissue
specimens provided by the National Center for Tumor Diseases tissue
bank were used in accordance to the regulations of the tissue bank and
under University of Heidelberg Ethics Committee approvals 206/
2005 and 207/2005. Patient samples were collected between 1990
and 2005 with a mean follow-up time of 80.7 months (range 0.3 to
254.7 months). A cohort of 26 patients with varying TNM stages was
retrieved from the archives of the Department of Pathology of the
University of Heidelberg School of Medicine and reviewed by an
expert pathologist (W.R.). The slides were processed as previously
described [12] and incubated with a PUMA antibody (Millipore
ABC158, 1:100 dilution). Additional antibodies used for immuno-
histochemistry were directed against cleaved caspase-3 (Cell Signal-
ing) and CD163 (Novocastra). Immunodetection was performed
using the Histostain Plus IHC Detection Kit (Life Technologies).
Slides were counterstained with hematoxylin.
Statistical Analysis
As an explorative study, all statistical analyses are of descriptive
nature. Statistical tests and resulting P values are not adjusted for
multiplicity and are therefore interpreted descriptively. A baseline
comparison between the two groups with PUMA positivity (group 1)
and the group with a reduced PUMA expression (group 2) was done
using the standard chi-square test. Prognostic factors for cancer-
specific survival were assessed by a univariable and different
multivariable Cox regression models. Because of the limited number
of patients within the considered subgroups, we only included three
covariates in the multivariable models to avoid overfitting. For
graphical display, Kaplan-Meier survival curves were generated, and
differences between groups were assessed using the log-rank test.
Student's t test for independent samples was used to compare
experimental groups. P values ≤ .05 were considered significant, and
Figure 1. PUMA expression and cancer-specific survival in a series of 673 RCCs.(A) Examples of PUMA-positive and PUMA-deficient RCC
tissue specimens from a TMA comprising more than 600 RCCs.(B) Kaplan-Meier curves for patient cohorts with either PUMA-deficient
tumors (green) or PUMA-positive tumors (blue). The postoperative cancer-specific survival of 673 patients is shown.
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the SPSS software package (SPSS) or GraphPad Prism (GraphPad).Results
PUMA Deficiency and Clinicopathological Characteristics in
RCC
Given the importance of PUMA for DNA damage-induced
apoptosis, we sought to determine whether and to what extent
primary RCCs have an altered baseline PUMA protein expression as a
potential cause for primary chemo- and radioresistance.
Using a TMA, a total of 673 RCCs were evaluated (Figure 1 and
Table 1). PUMA expression in RCCs was scored as either positive
(moderate to strong staining) or deficient (reduced or below detection
level; Figure 1A).Table 1. Patient Characteristics (n = 673)
Parameter n %
Sex
Male 420 62.4%
Female 253 37.6%
Age at diagnosis (years)
b65 366 54.4%
≥65 307 45.6%
Tumor stage
pT1/2 454 67.5%
pT3/4 219 32.5%
Lymph node metastasis
N0/pN0 628 93.3%
N+ 45 6.7%
Distant metastasis
M0 573 85.1%
M+ 100 14.9%
Fuhrman grade
G1/2 565 84%
G3/4 108 16%
Histology
Clear cell 579 86%
Papillary 59 8.8%
Chromophobe 27 4%
Others 8 1.2%A positive PUMA expression was found in 506 RCCs (75.2%). A
reduced expression was found in 152 tumors (22.6%). In addition, an
overexpression of PUMA was detected in 15 tumors (2.2%). The
latter group showed an overrepresentation of non–clear cell RCCs
including 60% papillary and 13.3% chromophobe RCCs and was
excluded from further analyses.
A statistical analysis of PUMA-positive RCCs in comparison to
PUMA-deficient tumors showed a correlation of the latter with less
aggressive tumor characteristics including lower TNM stage as well as
Fuhrman grade (Table 2). In line with this, Kaplan-Meier
cancer-specific survival curves showed that PUMA deficiency was
associated with more favorable cancer-specific patient survival
(Figure 1B). Cox regression analysis confirmed a borderline negative
prognostic impact of PUMA positivity versus PUMA deficiency in a
univariable analysis, but different multivariable Cox regression
models showed that PUMA expression was not an independent
prognostic factor (Table 3).
Taken together, our results demonstrate that PUMA deficiency is
associated with more favorable clinicopathological parameters and
cancer-specific survival in RCC patients.able 2. Correlation of PUMA Expression with Clinicopathological Parameters
UMA Expression Group 1: PUMA
Positive (n = 506)
Group 2: PUMA
Deficient (n = 152)
Significance *
ex (n; %) M (327; 64.6%) M (85; 55.9%) P = .052
F (179; 35.4%) F (67; 44.1%)
ge (n; %) b65 (284; 56.1%) b65 (77; 50.7%) P = .24
≥65 (222; 43.9%) ≥65 (75; 49.3%)
umor stage (n; %) pT1/2 (320; 63.3%) pT1/2 (122; 80.3%) P b .001
pT3/4 (186; 36.8%) pT3/4 (30; 19.7%)
ymph node metastasis
(n; %)
N0/pN0 (465; 91.9%) N0/pN0 (148; 97.4%) P = .019
pN+ (41; 8.1%) pN+ (4; 2.6%)
istant metastasis (n; %) M0 (421; 83.2%) M0 (138; 90.8%) P = .022
M+ (85; 16.8%) M+ (14; 9.2%)
uhrman grade (n; %) G1/2 (412; 81.4%) G1/2 (138; 90.8%) P = .006
G3/4 (94; 18.6%) G3/4 (14; 9.2%)
istology (n; %) Clear cell (428; 84.6%) Clear cell (147; 96.7%) P b .001
(clear cell vs
non–clear cell)
Papillary (47; 9.3%) Papillary (3; 2%)
Chromophobe (23; 4.5%) Chromophobe (2; 1.3%)
Others (8; 1.6%) Others (0; 0%)T
P
S
A
T
L
D
F
H* Chi-square test.
Table 3. Cox Regression Analysis.
Cancer-Specific Survival Univariable
Variable HR 95% CI P
PUMA (positive vs deficient) 1.46 1.02-2.09 .04
Age (N65 vs ≤65 years) 1.02 0.77-1.36 .88
Sex (female vs male) 0.62 0.46-0.84 .002
pT (pT3/4 vs pT1/2) 5.04 3.78-6.72 .000
N0/pN0 (+ vs 0) 7.35 5.17-10.45 .000
M (+ vs 0) 10.55 7.85-14.18 .000
Grade (G3/4 vs G1/2) 4.78 3.57-6.41 .000
Histology (clear cell vs non–clear cell) 1.70 1.03-2.79 .037
Cancer-Specific Survival Multivariable
Variables HR 95% CI P
PUMA (positive vs deficient) 0.93 0.65-1.35 .71
Sex (female vs male) 0.65 0.48-0.89 .006
pT (pT3/4 vs pT1/2) 4.94 3.69-6.61 .000
PUMA (positive vs deficient) 0.98 0.68-1.43 .93
pT (pT3/4 vs pT1/2) 3.97 2.91-5.43 .000
N0/pN0 (+ vs 0) 3.33 2.28-4.85 .000
PUMA (positive vs deficient) 0.86 0.60-1.23 .41
pT (pT3/4 vs pT1/2) 3.41 2.52-4.62 .000
M (+ vs 0) 7.22 5.29-9.85 .000
PUMA (positive vs deficient) 0.96 0.67-1.39 .84
pT (pT3/4 vs pT1/2) 3.71 2.70-5.09 .000
Grade (G3/4 vs G1/2) 2.59 1.88-3.57 .000
PUMA (positive vs deficient) 0.87 0.60-1.25 .45
pT (pT3/4 vs pT1/2) 4.86 3.62-6.52 .000
Histology (clear cell vs non–clear cell) 1.27 0.77-2.11 .35
PUMA (positive vs deficient) 0.78 0.54-1.12 .18
Grade (G3/4 vs G1/2) 4.52 3.36-6.08 .000
Histology (clear cell vs non–clear cell) 1.51 0.91-2.49 .11
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RCCs
To reconcile the perplexing finding that deficiency of the
proapoptotic protein PUMA correlates with more favorable tumor
characteristics, we directly tested the link between PUMA expressionFigure 2. PUMA, cleaved caspase, and CD163 expression in cc
PUMA-positive ccRCC for cleaved caspase-3 and CD163. Scale bar =and apoptosis in a cohort of 26 primary clear cell RCCs
(ccRCCs). The tumors were chosen to represent a wide range of
pTNM stages including 7 pT1N0M0, 10 rarely seen pT1N0M1, and
9 pT3/4 ccRCCS with or without synchronous lymph node or
distant metastases.
In addition to PUMA, we stained adjacent sections for cleaved
caspase-3 to visualize apoptotic cells and the macrophage marker
CD163 (Figure 2). The latter marker has been used to detect
tumor-associated macrophages (TAMs) of the M2 phenotype, which
have been implicated in tumor growth promotion and metastasis
[13,14]. The rationale for this experiment was that PUMA deficiency
could lead to a reduced frequency of apoptotic cells and, as a
consequence, a diminished infiltration with tumor-promoting M2
TAMs and ultimately an attenuation of malignant progression.
We identified 11 PUMA-deficient ccRCCs (b1 positive cell per
40× high-power field, HPF) of 26 tumors analyzed (42.3%; Figure 3).
The 15 tumors that were PUMA positive (57.7%) showed an average
of 42 positive cells per 40× HPF. The average frequency of apoptotic
cells was 12.7 per HPF in PUMA-deficient tumors and 5.2 in
PUMA-positive tumors, but this trend toward more apoptosis in
PUMA-deficient tumors did not reach statistical significance (P N
.05). The average frequency of CD163-positive cells was 23.6 per
HPF in PUMA-deficient tumors and 20.3 in PUMA-positive tumors,
which was also not statistically significant (P N .05; Figure 3).
Remarkably, the highest level of apoptotic cells and TAM infiltration
was detected in a PUMA-deficient ccRCC (Figure 3). The average
frequency of CD163-positive TAMs in tumors in which no apoptotic
cells were detected (n = 9) was 15.2 per HPF versus 25.1 per HPF in
tumors in which apoptotic cells were present (n = 17; P N .05).
These findings underscore that PUMA expression and apoptosis
are frequently uncoupled in RCC.
Functional Heterogeneity of PUMA Expression and Apoptosis
Induction In Vitro
To corroborate these tissue-based results on a functional level, we
used a panel of six RCC cell lines and noncancerous HEK293 cells for
further analyses (Figure 4). First, we determined the baselineRCCs.Immunohistochemical analysis of a PUMA-deficient and
50 μm.
Figure 3. PUMA expression and apoptosis induction are disconnected in ccRCCs.Quantification of staining results from a total of 26
ccRCCs. pTNM and Fuhrman grade are indicated for each tumor. Each bar indicates mean and standard error of the number of positively
stained cells from 10 HPFs (40×).
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differences between cell lines (Figure 4A). To exploit this fact, we
determined apoptotic cell death, as measured by caspase 3/7 activties,
following a 24-hour exposure of cells to proapoptotic stimuli using
either the protein kinase C inhibitor staurosporine or the DNA
damaging agent daunorubicin at two concentrations (Figure 4B). The
highest induction of apoptosis (9.6-fold) was detected in A-498 cells
treated with 1 μM daunorubicin, a cell line with virtually
undetectable PUMA protein expression. The second highest
induction of apoptosis (6.2-fold; 1 μM daunorubicin) was found in
Caki-1 cells with very low PUMA protein expression. Under these
short-term treatment conditions, HEK293, which had the highest
level of PUMA protein expression, did not undergo enhancedapoptosis, most likely because these cells require a longer time interval
as suggested by previous experiments[11]. PUMA-expressing ACHN
cells showed a 4.1-fold increase of apoptosis in response to 1 μM
daunorubicin, which was clearly below A-498 and Caki-1 cells, both
of which had significantly lower PUMA expression. There was a trend
toward more pronounced apoptotic responses to staurosporine than
daunorubicin in 786-0, Caki-2, and RCC-KP cells. This underscores
that the mode of apoptosis induction is relevant for the cellular
response. The fact treatment with 10 μM daunorubicin led to less
apoptosis in some RCC cells reflects the well-known fact that higher
drug concentrations shift peak caspase activation and/or lead to
nonapoptotic cell death. To rule out nonspecific effects that may have
influenced these results, e.g., differences in cell cycle distribution, we
Figure 4. PUMA expression and apoptosis are uncoupled in vitro.(A) Immunoblot analysis of PUMA expression in six RCC cell lines and
noncancerous HEK293 cells. Immunoblot for GAPDH is shown to demonstrate protein loading.(B) Quantification of apoptosis induction
by staurosporine or daunorubicin (24 hours) at the concentrations indicated. Fold changes are shown after normalization to DMSO.
Asterisks indicate the level of statistical significance (*P≤ .05; **P≤ .005).(C, D) Immunoblot analysis of RCC cell lines and HEK293 cells
for p53 and phospho-p53 S15 under the same experimental conditions as in (B). GAPDH is shown to demonstrate protein loading.
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(Figure 4, C and D). Our results show that all cell lines show an
activation of p53 as measured by serine 15 phosphorylation.
Taken together, these results highlight the remarkable functional
heterogeneity of RCC cells and the profound disconnect between
PUMA expression and apoptosis induction.Discussion
PUMA is a key mediator of p53-induced apoptosis following various
insults including genotoxic stress [5]. Here, we analyzed PUMA
protein expression in a series of more than 600 RCCs and found an
unexpected correlation between PUMA deficiency and more
favorable clinicopathological characteristics including cancer-specific
486 Functional Heterogeneity in Renal Cell Carcinoma Zhou et al. Translational Oncology Vol. 8, No. 6, 2015patient survival. To reconcile these findings, we show that loss of
PUMA does not necessarily confer apoptosis resistance. In fact, the
average frequency of apoptotic cells was higher in PUMA-deficient
tumors in comparison to PUMA-positive tumors, although this
difference did not yield statistical significance. In addition, a series of
in vitro experiments underscores the remarkable functional hetero-
geneity of RCC cells and showed the highest level of apoptosis in
PUMA-deficient cells.
Although our finding that patients with PUMA-deficient tumors
had a survival advantage was initially perplexing, the presence of
PUMA-independent apoptosis as shown here both in vivo and in
vitro may explain this result. How precisely caspase-dependent
apoptosis in response to genotoxic stress is executed when PUMA is
absent or reduced requires further experimental analysis. Although
the existence of PUMA-independent caspase activation and apoptosis
induction has previously been reported in colon cancer cells as well as
neuronal cells [15,16], the underlying mechanisms remain unclear.
There is the possibility of autoactivation of caspases under certain
stress conditions such as proteasome inhibition [16]. Whether this
explains the results shown here remains to be tested, but it is
noteworthy that RCC cell lines with apoptosis induction following
DNA damage also responded to staurosporine, which suggests a more
general propensity to undergo apoptosis or not. Another possible
scenario is that p53 activation triggers a death receptor pathway-me-
diated induction of apoptosis as previously reported [17]. However,
our finding that p53 activation was basically identical in the presence
or absence of apoptosis speaks against this notion.
Almost all members of pro- and antiapoptotic proteins of the
BCL-2 family have been shown to be altered in RCC [7–9,18,19].
This report extends this knowledge by adding PUMA to the group of
proapoptotic proteins that are frequently disrupted in RCC.
Nevertheless, the remarkable functional heterogeneity of RCC cells
requires further consideration. PUMA-deficient cells can be either
highly susceptible to rapid apoptosis induction as shown here or
resistant to cell death unless PUMA is reactivated by HDAC
inhibition as previously shown [11]. Conversely, PUMA-proficient
cells may or may not show a propensity to undergo apoptosis under
conditions used here with ACHN cells as examples of the former and
HEK293 cells as examples of the latter. It is hence conceivable that
PUMA expression status alone may not be suitable to predict the
response to DNA damage-inducing therapies. However, our report
also underscores the importance of PUMA-independent cell death
pathways in RCC. Understanding and harnessing these pathways
should hence be an integral part of innovative strategies to resensitize
RCC cells to DNA damaging agents to improve oncological
treatment modalities for advanced RCC patients.
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